Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners.
Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.
Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Epitopea, Storm Therapeutics, Immutrin, PredictImmune, Sense Bio and Start Codon.
He is also on the board of Cambridge&, an organisation dedicated to attracting the highest quality individuals and organisations from around the globe into the Cambridge ecosystem.
A new approach to precision-guided therapies
Revealing the likely direction of disease
First-in-class therapies targeting RNA modifying enzymes
Redefining diagnostics at the point-of-care